OH-UWL
26.4.2022 19:42:09 CEST | Business Wire | Press release
UWL, a top 10 American-owned NVOCC and leading provider of global 3PL services, has contracted with Swire Shipping, a multi-purpose liner service, to launch a new, exclusive express service, departing from Ho Chi Minh City and arriving at the Port of Seattle in 18 days. Providing speed and predictability, the bi-weekly service offers the fastest trip from Vietnam to the US. This revolutionary agreement is the first dedicated ocean service by an NVOCC in the trade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006070/en/
“Customers have been asking for creative solutions during this extremely challenging market, and this first-of-its-kind service is part of our response. Congestion and rate spikes will come and go, but the root issues remain. US importers are pushing for more creativity and controlled reliable solutions to manage supply chain risk,” UWL President Duncan Wright said.
The service offers priority berthing at both origin and destination, and a dedicated equipment pool for suppliers in Ho Chi Minh City. This includes 6,000 brand-new ocean containers, with 40-foot-high cube and 20-foot containers already in the rotation. Predictability is assured, as schedules are published six months in advance, with two sailings per month.
Upon arrival in Seattle, those needing warehousing or distribution space can take advantage of UWL’s sister company, World Distribution Services (WDS), and its brand-new 300,000 sq. ft. facility near Tacoma, WA, just a short drive away from the Port of Seattle.
“In joining forces with UWL, an innovative and integrated logistics provider to American BCOs, we are confident that our ocean express solution will be compelling to importers and exporters who need a direct port-to-port, fast, and reliable service between Vietnam and the Pacific Northwest,” said Rufus Frere-Smith, Regional Head, Americas, Swire Shipping, which facilitates trade in more than 90 countries and across 400 ports. “Our partnership is built on a joint vision of responding to customers’ desire for reliable, safe, and innovative shipping solutions.”
Mr. Wright noted: “We have seen incredibly strong demand for this service already, which tells us that fast and reliable niche services are here to stay. Our relationship with Swire Shipping is critical to making all this work. Their remarkable 150-year history and robust knowledge of ocean shipping and strong Asia legacy, combined with UWL’s culture of innovation, brings this dedicated service to life.”
Mr. Frere-Smith commented: “We have deployed new state-of-the-art, fuel-efficient vessels that will sail at high speed, safely and sustainably. We are confident customers and BCOs will find this direct, express service to be extremely effective in shipping their high value products and getting to market quickly.”
About UWL
UWL is a top 10 American-owned NVOCC and leading provider of global 3PL services. They take pride in delivering seamless supply chain solutions backed by a team of creative problem-solvers. Specializing in ocean transportation, air freight, road and rail, warehousing and distribution, project cargo, and customs house brokerage, their proof is in owned assets: a national network of distribution centers, dependable trucking capacity, and WorldScope , a user-friendly data management platform that delivers transparency and visibility customers can count on. Wherever your freight needs to go, they can help get it there. To find out more, visit their website at www.shipuwl.com
About Swire Shipping
Swire Shipping is a privately owned organization that was founded in 1872 and now comprises over 600 employees in 20 countries and owns and deploys over 30 vessels in the intra-Asia, Australasia, and Polynesia trades. It is part of the Swire Group which is a Hong Kong- and London-based British conglomerate. Many of its core businesses can be found within the Asia Pacific region, where traditionally Swire’s operations have centered on Hong Kong and mainland China. Its subsidiaries include Cathay Pacific Airlines, Swire Properties, China Navigation Company, Swire Hotels and Swire Resources.
About World Group
World Group was founded over 60 years ago as a pioneer in vessel agency services on the Great Lakes. Today, they are home to a portfolio of globally trusted brands that deliver customers end-to-end supply chain and logistics solutions, including ContainerPort Group, UWL, World Distribution Services, and World Shipping, Inc. With industry-leading products in ocean drayage and domestic trucking, freight forwarding and air freight, customs house brokerage, vessel husbandry, and warehousing and distribution, customers around the globe use their services to simplify supply chains and reliably move freight.
Offering career opportunities across the country for innovators in the transportation industry, their award-winning culture is anchored in people who live and breathe the company’s core values daily. Learn how to join the World Group family by visiting their careers page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom